Scholar Rock Announces the Addition of Katie Peng to Its Board of Directors and Promotes Mo Qatanani, Ph.D. to Chief Scientific Officer CAMBRIDGE, Mass.--(BUSINESS WIRE)

Scholar Rock Announces

the Addition of Katie Peng to Its Board of Directors and

Promotes Mo Qatanani,

Ph.D. to Chief Scientific Officer

CAMBRIDGE, Mass.--(BUSINESS

WIRE)- February 15, 2024-- Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical

company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases

where protein growth factors play a fundamental role, today announced the appointment of Katie Peng to Scholar Rock's Board

of Directors and the promotion of Mo Qatanani, Ph.D., to Chief Scientific Officer.

"We are pleased to welcome Katie to

Scholar Rock's Board of Directors at a pivotal time when the company is preparing for the potential launch of apitegromab next year,"

said David Hallal, Chairman of the Board of Scholar Rock. "Katie brings deep commercial expertise in neurology and rare diseases

and has a strong understanding of SMA from her experience launching Evrysdi while she was a business unit head at Genentech. Katie joining

our Board reflects the continued evolution of Scholar Rock, and as part of this process, Amir Nashat will be stepping down from the Board

at this year's annual shareholder meeting. Amir has made significant contributions to the growth of Scholar Rock since joining the

board in 2012, and we extend our sincere gratitude to him for his unwavering dedication to the company."

Ms. Peng is an accomplished biotechnology

executive with over three decades of deep commercial experience in neurology and rare diseases, and she is currently the Chief Commercial

Officer at Denali Therapeutics. Prior to joining Denali, Ms. Peng managed a neurology, ophthalmology, immunology, and rare disease

portfolio representing approximately $14 billion in revenue at Genentech. She has successfully launched multiple products in neurology,

oncology, and rare disease, notably Evrysdi (risdiplam) at Genentech, a medicine used to treat spinal muscular atrophy (SMA) in adults

and children. Before that, Ms. Peng was at Roche Holding AG, where she was the General Manager of both Taiwan and Singapore, managing

the portfolio of over 30 products in the Asia Pacific region. Earlier in her career, she held multiple commercial roles at Amgen Inc.

and was a research scientist at Allergan plc. Ms. Peng holds an MBA from the Kelley School of Business, Indiana University and

a B.A. from the University of California, Berkeley. She also serves as a board member for California Life Sciences and Adicet Bio.

"I am thrilled to join Scholar Rock's

Board of Directors as the company prepares for its first potential commercial launch of apitegromab. I look forward to working with the

team and sharing my experience and expertise to successfully bring apitegromab to people living with SMA," said Ms. Peng.

"In addition to having Katie join our

Board, I am excited by the continued progress of our preclinical programs, including additional work in developing SRK-439 for cardiometabolic

disorders. Mo has been a driving force in advancing our early-stage pipeline, especially the cardiometabolic program, and it is my pleasure

to announce his promotion to Chief Scientific Officer. He has been an outstanding leader of our research organization and a key member

of the leadership team," said Jay Backstrom, M.D., MPH, President and Chief Executive Officer of Scholar Rock.

Dr. Qatanani joined Scholar Rock in 2021

and, since 2022, has been leading all research functions, including discovery biology, protein sciences & antibody engineering,

nonclinical safety, and translational sciences. He brings over 15 years of discovery and translational research experience in developing

and advancing multiple therapeutic modalities in the neuromuscular and cardiometabolic disease areas.

Prior to Scholar Rock, Dr. Qatanani was

a founding employee, vice president, and Head of Research at Dyne Therapeutics, where he built the research organization from the ground

up to launch and advance to the clinic multiple therapeutic programs for rare neuromuscular diseases. Before that, he held research positions

of increasing responsibility at Alexion Pharmaceuticals, Synageva BioPharma, and Merck. Dr. Qatanani holds a Ph.D. in Molecular and

Human Genetics from Baylor College of Medicine and completed a post-doctoral fellowship at the Institute for Diabetes, Obesity and Metabolism

at the University of Pennsylvania School of Medicine. He has a B.Sc. and a M.Sc. in Biology from the American University of Beirut.

"Scholar Rock is known for its pioneering

scientific research, particularly in the unparalleled selective targeting of the latent forms of growth factors, and I am proud to be

able to lead these efforts during this exciting stage of the company's growth, and to help translate this groundbreaking science

into transformative therapies that have the potential to improve peoples' lives," said Dr. Qatanani.

Scholar Rock is a biopharmaceutical company that discovers, develops,

and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of

the transforming growth factor beta (TGF ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to

protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental.

Over the past decade, Scholar Rock has created a pipeline with the potential to advance the standard of care for neuromuscular disease,

cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role.

Scholar Rock is the only company to show clinical proof of concept

for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches

is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth

factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through

traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about our approach at ScholarRock.com

and follow @ScholarRock and on LinkedIn.

Availability of Other Information About Scholar Rock

Investors and others should note that we communicate with our investors

and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations

and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well

as on Twitter and LinkedIn. The information that we post on our website or on Twitter or LinkedIn could be deemed to be material information.

As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis.

The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933,

Scholar Rock is a registered trademark of Scholar Rock, Inc.

Forward-Looking Statements

This press release contains "forward-looking statements"

within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Scholar

Rock's future expectations, plans and prospects, including without limitation, Scholar Rock's expectations regarding its growth,

strategy, progress and development timing, the ability of any individual to affect the growth, strategy, and progress of Scholar

Rock, and the potential of its product candidates and proprietary platform. The use of words such as "may," "might,"

"could," "will," "should," "expect," "plan," "anticipate," "believe,"

"estimate," "project," "intend," "future," "potential," or "continue,"

and other similar expressions are intended to identify such forward-looking statements. All such forward-looking statements are based

on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results

to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties

include, without limitation, Scholar Rock's ability to provide the financial support, resources and expertise necessary to identify

and develop product candidates on the expected timeline, the data generated from Scholar Rock's nonclinical and preclinical studies

and clinical trials, and Scholar Rock's ability to manage expenses and to obtain additional funding when needed to support its business

activities and establish and maintain strategic business alliances and new business initiatives, as well as those risks more fully discussed

in the section entitled "Risk Factors" in Scholar Rock's Quarterly Report on Form 10-Q for the year ended September 30,

2023, as well as discussions of potential risks, uncertainties, and other important factors in Scholar Rock's subsequent filings

with the Securities and Exchange Commission. Any forward-looking statements represent Scholar Rock's views only as of today

and should not be relied upon as representing its views as of any subsequent date. All information in this press release is as of the

date of the release, and Scholar Rock undertakes no duty to update this information unless required by law.